Bausch & Lomb, Nicox Seek FDA Approval for Vesneo

Bausch & Lomb and Nicox are calling their once-daily eye drop for treating both open angle glaucoma and ocular hypertension a milestone in research and development in a medical area that has seen few new treatments in recent years.

The companies are seeking an NDA from the FDA for Vesneo (latanoprostene bunod), designed to reduce pressure on the eye by using nitric oxide signaling, lipid binding and latanoprost acid to move fluids out of optic canals more easily.

Licensed to B&L by French eye drug maker Nicox, Vesneo is the first truly novel intraocular pressure lowering medication in recent years, the company says. 

Indian pharmaceutical company Lupin received ANDA approval in February to market a generic version of Allergan’s Lumigan.

The PDUFA date is July 21, 2016. — Victoria Pelham